格隆汇11月3日丨华绿生物(300970.SZ)在投资者互动平台表示，舞茸目前在公司营业收入中占比较少， 仍处于市场拓展阶段。 ...

Core Viewpoint - The company, Hualv Biotechnology, has reported a significant increase in revenue projections for 2024, reaching 1.032 billion yuan, up from 578 million yuan in 2021, indicating strong growth in its product offerings and market expansion [1] Product Offerings - The main products of the company include enoki mushrooms, true shiitake mushrooms (which encompass varieties such as crab-flavored and white jade mushrooms), maitake mushrooms, cordyceps flowers, and deer antler mushrooms [1] - Cordyceps flowers and deer antler mushrooms are newly launched products post-IPO, showcasing the company's commitment to diversifying its product range [1] Revenue Growth - The projected revenue for 2024 is 1.032 billion yuan, which represents a notable increase compared to the 578 million yuan reported in 2021, highlighting the company's growth trajectory [1]

Core Viewpoint - The company, Hualv Biotechnology, has reported significant growth in its product offerings and revenue, projecting a revenue of 1.032 billion yuan in 2024, which represents a substantial increase from 578 million yuan in 2021, indicating a doubling of both production capacity and revenue [1]. Group 1: Product Diversification - The main products of the company include enoki mushrooms, king oyster mushrooms (including crab-flavored and white jade varieties), maitake mushrooms, cordyceps flowers, and deer antler mushrooms, with the latter two being introduced after the company's IPO [1]. - The company has achieved industrialized production of edible mushroom products under its diversified layout, with ongoing inquiries about new specialty varieties [3]. Group 2: Capacity and Revenue Growth - The company anticipates that its revenue for 2024 will reach 1.032 billion yuan, which is a notable increase from 578 million yuan in 2021, reflecting a clear growth trajectory [1]. - The company has successfully doubled its production capacity and revenue since its listing, with specific inquiries regarding the new and expanded production bases planned for 2024 and 2025 [3].

Group 1 - Jiangsu's import and export to ASEAN reached 791.73 billion yuan from January to September, a year-on-year increase of 22.8% [1] - New麦机械 (China) Co., Ltd. has seen a surge in production, with orders from Vietnam valued at 250,000 yuan, benefiting from a tariff reduction of 11,000 yuan due to the China-ASEAN Free Trade Area certificate [1] - The company applied for 190 certificates related to the China-ASEAN Free Trade Area, involving a value of nearly 71 million yuan, which is a year-on-year increase of 6.98% [1] Group 2 - Jiangsu Hualu Biotechnology Group has successfully exported 1,133.18 tons of edible mushrooms to ASEAN, marking a nearly 80% year-on-year increase [1] - The company is a key player in the local edible mushroom industry, with products like enoki mushrooms and white mushrooms entering Southeast Asia and South America [1] - A textile printing and dyeing production base was established in Vietnam, leading to over 9 million yuan in exports to ASEAN and enjoying tariff benefits exceeding 300,000 yuan [2]

Group 1 - Jiangsu's import and export to ASEAN reached 791.73 billion yuan from January to September, a year-on-year increase of 22.8% [1] - New麦机械 (China) Co., Ltd. exported baking machinery worth 250,000 yuan to Vietnam, benefiting from a tariff reduction of 11,000 yuan due to the China-ASEAN Free Trade Area origin certificate [1] - Jiangsu华绿生物科技集团 Co., Ltd. exported 1,133.18 tons of edible mushrooms to ASEAN, a nearly 80% year-on-year increase [1] Group 2 - Jiangsu红柳床单有限公司 established a textile printing and dyeing production base in Vietnam, achieving over 9 million yuan in exports to ASEAN and benefiting from over 300,000 yuan in tariff reductions [2]

Group 1 - The company, Hualv Biotechnology, announced on September 25 that it will promote its products through periodic online live broadcasts [2] - The company's mushroom products are available for sale online through platforms such as Dingdong and Meituan, as well as in major wholesale markets nationwide [2] - The company encourages consumers to purchase its products [2]

Core Viewpoint - The company is currently the only one in the industry that has industrialized production of maitake mushrooms, with no other competitors known to have similar capabilities [1] Group 1 - The company responded to investor inquiries on September 25, indicating its unique position in the market [1] - The company has not identified any other listed companies in the same industry that are engaged in industrialized production of maitake mushrooms [1]

Group 1 - The core viewpoint is that Hualu Bio has achieved a breakthrough in the industrialized cultivation technology of Grifola frondosa (Maitake mushroom), positioning itself as a leader in the industry [2] - According to Hualu Bio, it is currently the only listed company in the industry that has implemented industrialized production of Maitake products, with no other companies known to have achieved this [2]

Core Viewpoint - The company Hualu Bio (300970.SZ) has stated that its maitake mushroom products are not currently positioned in the pharmaceutical industry [1] Company Summary - Hualu Bio has clarified its current strategic focus, indicating that it has not yet ventured into the pharmaceutical sector with its maitake mushroom products [1]

Group 1 - Core viewpoint: Hualu Bio experienced a 5.01% decline on August 27, with a stock price of 14.80 yuan per share and a total market capitalization of 1.779 billion yuan [1] - Company overview: Jiangsu Hualu Bio-Tech Group Co., Ltd. was established on June 8, 2010, and listed on April 12, 2021. The company specializes in the research, industrial cultivation, and sales of edible mushrooms [1] - Revenue composition: The main business revenue is derived from enoki mushrooms (69.15%), king oyster mushrooms (25.44%), maitake mushrooms (2.65%), other products (1.50%), and cordyceps flowers (1.26%) [1] Group 2 - Major shareholder: CITIC Prudential Fund's multi-strategy mixed fund (LOF) A (165531) increased its holdings by 1.2423 million shares in the second quarter, holding a total of 2.0213 million shares, which represents 2.18% of the circulating shares [2] - Fund performance: The fund has achieved a return of 41.61% year-to-date, ranking 893 out of 8194 in its category, and an annual return of 80.96%, ranking 656 out of 7963 [2] - Fund manager details: The fund manager Jiang Feng has a tenure of 5 years and 137 days, with a total asset scale of 5.782 billion yuan, while Wang Ying has a tenure of 8 years and 195 days, managing 3.835 billion yuan [3]